CORALVILLE, Iowa, July 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Canaccord Genuity 36th Annual Growth Conference being held August 10-11, 2016, at the InterContinental Boston Hotel.
Details of KemPharm's presentation are as follows:
Date: Thursday, August 11, 2016
Time: 1:00 PM (ET)
Location: InterContinental Boston Hotel, 510 Atlantic Ave., Boston, MA 02210
The presentation will be webcast and available on the Investor Relations section of the Company's website at http://investors.kempharm.com/.
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its LAT platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 email@example.com firstname.lastname@example.org Media Contact: Jim Heins Cooney Waters Unlimited 212-886-2221 email@example.com